May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Levofloxacin Susceptibility in Multi–Drug–Resistant S. pneumoniae Isolates from the Nationwide TRUST Surveillance Study, 2000–2004
Author Affiliations & Notes
  • C.N. Ta
    Ophthalmology, Stanford University, Palo Alto, CA
  • D.F. Sahm
    Focus Bio–Inova, Herndon, VA
  • A. Ingerman
    Johnson & Johnson, Skillman, NJ
  • Footnotes
    Commercial Relationships  C.N. Ta, Santen, F; D.F. Sahm, Ortho–McNeil Pharmaceutical, F; A. Ingerman, Johnson & Johnson, E.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3573. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.N. Ta, D.F. Sahm, A. Ingerman; Levofloxacin Susceptibility in Multi–Drug–Resistant S. pneumoniae Isolates from the Nationwide TRUST Surveillance Study, 2000–2004 . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3573.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Since the early 1990s, pneumococcal resistance to many common antibiotics has risen steadily in the United States. Because resistant organisms can survive and acquire resistance to multiple antibiotics, the prevalence of multi–drug–resistant Streptococcus pneumoniae (MDRSP) strains has increased as well. Levofloxacin has been available to treat systemic infections for >9 years and is the new–generation fluoroquinolone most widely used as oral/IV therapy for systemic infections. Levofloxacin is also commonly used to treat ophthalmic infections. We assessed changes in levofloxacin susceptibility over time in MDRSP isolates collected in TRUST, an annual surveillance study that monitors antimicrobial susceptibility in isolates collected from >200 institutions in all 50 states.

Methods: : TRUST (Tracking Resistance in the U.S. Today) is an annual surveillance of antimicrobial resistance designed to detect changes in antimicrobial susceptibility patterns. Antimicrobial minimum inhibitory concentrations (MICs) in MDRSP isolates (resistant to >2 classes of antimicrobials) were determined by broth microdilution. Levofloxacin MIC susceptible breakpoint: <2.0 µg/mL.

Results: : In four respiratory seasons (2000–2004), 22,794 S. pneumoniae isolates were collected by institutions participating in TRUST; 99% of these isolates were levofloxacin–susceptible. Multi–drug resistance (resistance to >2 drug classes) was identified in 4,704 S. pneumoniae isolates (21% of all isolates); 98% of these MDRSP isolates were susceptible to levofloxacin. 601 MDRSP isolates were 4–drug resistant and 294 isolates were 5–drug resistant (cephalosporin, macrolides, penicillin, tetracycline, and trimethoprim/sulfamethoxazole); 98% of both 4– and 5–drug resistant MDRSP isolates remained levofloxacin–susceptible. MDRSP susceptibility to levofloxacin changed <1% from year to year.

Conclusions: : Despite >9 years of levofloxacin use, susceptibility of MDRSP to levofloxacin remains high.

Keywords: antibiotics/antifungals/antiparasitics • clinical laboratory testing 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.